Bliss GVS Pharma Limited has informed the Exchange regarding 'Annual Secretarial Compliance Report for the year ended March 31, 2026'.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bliss GVS Pharma Limited has filed its Annual Secretarial Compliance Report for FY 2025-26, examined by AVS & Associates, Practicing Company Secretaries. The report shows the company largely complied with SEBI regulations across 13 compliance areas including secretarial standards, insider trading norms, related party transactions, and document preservation. However, one contra trade was executed by a Designated Person during the review period, raising an insider trading concern — the company is taking corrective action. The report also notes that the company paid fines of Rs. 66,000 each to BSE and NSE for a prior period violation related to appointment of a director aged above 75 years without prior shareholder approval. Management stated it has strengthened internal processes to ensure timely regulatory compliance going forward.
The filing is largely positive for shareholders as the company maintained compliance across most SEBI requirements. However, the contra trade by a Designated Person represents a minor red flag regarding insider trading controls, which investors should monitor. The resolved fine matter from the prior year does not pose ongoing concern.